Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
EnerCom Announces SM Energy as a Keynote Speaker at the 31st EnerCom Denver - The Energy Investment Conference, on August 19, 2026, in Denver, Colorado